Monopar Therapeutics Inc. Research and Development Expense
Monopar Therapeutics Inc. (MNPR) reported Research and Development Expense of $4.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Monopar Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $4.77M, a 175.54% increase year-over-year.
- Monopar Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $3.49M, a 112.20% increase year-over-year.
- Monopar Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $3.94M, a 60.29% decline year-over-year.
- Monopar Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $2.59M, a 163.11% increase year-over-year.
- Monopar Therapeutics Inc. research and development expense for fiscal 2025 was $9.90M, a 23.85% decline from fiscal 2024.
- Monopar Therapeutics Inc. research and development expense for fiscal 2024 was $13.01M, a 132.24% increase from fiscal 2023.
- Monopar Therapeutics Inc. research and development expense for fiscal 2023 was $5.60M, a 26.23% decline from fiscal 2022.
- Monopar Therapeutics Inc. research and development expense for fiscal 2022 was $7.59M, a 16.92% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.77M 10-Q · filed 2026-08-12 | $8.25M 10-Q · filed 2026-08-12 | $12.20M derived: sum of 3 quarters · filed 2026-08-12 | $14.78M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $3.49M 10-Q · filed 2026-05-14 | $7.43M derived: sum of 2 quarters · filed 2026-05-14 | $10.02M derived: sum of 3 quarters · filed 2026-05-14 | $11.75M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $6.53M derived: sum of 2 quarters · filed 2026-03-27 | $8.26M derived: sum of 3 quarters · filed 2026-08-12 | $9.90M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-13 | $4.32M derived: sum of 2 quarters · filed 2026-08-12 | $5.96M 10-Q · filed 2025-11-13 | $15.89M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $1.73M 10-Q · filed 2026-08-12 | $3.37M 10-Q · filed 2026-08-12 | $13.30M derived: sum of 3 quarters · filed 2026-08-12 | $14.28M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $1.64M 10-Q · filed 2026-05-14 | $11.57M derived: sum of 2 quarters · filed 2026-05-14 | $12.55M derived: sum of 3 quarters · filed 2026-05-14 | $13.68M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $10.91M derived: sum of 2 quarters · filed 2026-03-27 | $12.04M derived: sum of 3 quarters · filed 2026-03-27 | $13.01M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $984.28K 10-Q · filed 2025-11-13 | $2.12M derived: sum of 2 quarters · filed 2025-11-13 | $3.08M 10-Q · filed 2025-11-13 | $4.12M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.13M 10-Q · filed 2025-08-12 | $2.10M 10-Q · filed 2025-08-12 | $3.13M derived: sum of 3 quarters · filed 2025-08-12 | $4.45M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $966.11K 10-Q · filed 2025-05-13 | $2.00M derived: sum of 2 quarters · filed 2025-05-13 | $3.32M derived: sum of 3 quarters · filed 2025-05-13 | $4.91M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.35M derived: sum of 2 quarters · filed 2025-03-31 | $3.95M derived: sum of 3 quarters · filed 2025-03-31 | $5.60M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.32M 10-Q · filed 2024-11-08 | $2.91M derived: sum of 2 quarters · filed 2024-11-08 | $4.56M 10-Q · filed 2024-11-08 | $6.67M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $1.59M 10-Q · filed 2024-08-09 | $3.25M 10-Q · filed 2024-08-09 | $5.35M derived: sum of 3 quarters · filed 2024-08-09 | $7.08M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | $1.65M 10-Q · filed 2024-05-09 | $3.76M derived: sum of 2 quarters · filed 2024-05-09 | $5.49M derived: sum of 3 quarters · filed 2024-05-09 | $7.57M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.84M derived: sum of 2 quarters · filed 2024-03-28 | $5.91M derived: sum of 3 quarters · filed 2024-03-28 | $7.59M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $1.73M 10-Q · filed 2023-11-09 | $3.81M derived: sum of 2 quarters · filed 2023-11-09 | $5.49M 10-Q · filed 2023-11-09 | $7.47M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.08M 10-Q · filed 2023-08-10 | $3.76M 10-Q · filed 2023-08-10 | $5.74M derived: sum of 3 quarters · filed 2023-08-10 | $7.57M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $1.68M 10-Q · filed 2023-05-11 | $3.66M derived: sum of 2 quarters · filed 2023-05-11 | $5.49M derived: sum of 3 quarters · filed 2023-05-11 | $6.96M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $3.81M derived: sum of 2 quarters · filed 2023-03-23 | $5.29M derived: sum of 3 quarters · filed 2023-03-23 | $6.49M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $1.83M 10-Q · filed 2022-11-10 | $3.30M derived: sum of 2 quarters · filed 2022-11-10 | $4.51M 10-Q · filed 2022-11-10 | $6.14M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.48M 10-Q · filed 2022-08-11 | $2.68M 10-Q · filed 2022-08-11 | $4.32M derived: sum of 3 quarters · filed 2022-08-11 | $5.57M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-12 | $2.84M derived: sum of 2 quarters · filed 2022-05-12 | $4.10M derived: sum of 3 quarters · filed 2022-05-12 | $4.93M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $2.89M derived: sum of 2 quarters · filed 2022-03-24 | $3.72M derived: sum of 3 quarters · filed 2022-03-24 | $4.07M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $1.26M 10-Q · filed 2021-11-12 | $2.09M derived: sum of 2 quarters · filed 2021-11-12 | $2.43M 10-Q · filed 2021-11-12 | $3.02M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $832.50K 10-Q · filed 2021-08-12 | $1.18M 10-Q · filed 2021-08-12 | $1.76M derived: sum of 3 quarters · filed 2021-08-12 | $1.98M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $344.41K 10-Q · filed 2021-05-13 | $928.18K derived: sum of 2 quarters · filed 2021-05-13 | $1.15M derived: sum of 3 quarters · filed 2021-05-13 | $1.48M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $583.78K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $803.62K derived: sum of 2 quarters · filed 2021-03-25 | $1.13M derived: sum of 3 quarters · filed 2021-03-25 | $1.97M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $219.85K 10-Q · filed 2020-11-12 | $549.14K derived: sum of 2 quarters · filed 2020-11-12 | $1.38M 10-Q · filed 2020-11-12 | $1.91M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $329.29K 10-Q · filed 2020-08-06 | $1.16M 10-Q · filed 2020-08-06 | $1.69M derived: sum of 3 quarters · filed 2020-08-06 | $1.99M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $835.60K 10-Q · filed 2020-05-07 | $1.36M derived: sum of 2 quarters · filed 2020-05-07 | $1.66M derived: sum of 3 quarters · filed 2020-05-07 | $1.96M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $520.98K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $824.67K derived: sum of 2 quarters · filed 2020-03-27 | $1.13M derived: sum of 3 quarters · filed 2020-03-27 | $1.77M 10-K · filed 2020-03-27 | |
| 2018-09-30 | $303.68K 10-Q · filed 2018-11-09 | $607.37K derived: sum of 2 quarters · filed 2019-11-12 | $1.25M 10-Q · filed 2019-11-12 | $1.37M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $303.68K 10-Q · filed 2019-11-12 | $492.65K 10-Q · filed 2018-08-09 | $949.79K 10-Q · filed 2019-08-08 | $1.07M derived: sum of 3 quarters · filed 2019-11-12 | $1.25M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-03-31 | $457.14K 10-Q · filed 2019-05-10 | $766.46K derived: sum of 2 quarters · filed 2019-05-10 | $947.13K derived: sum of 3 quarters · filed 2019-05-10 | $1.26M derived: sum of 4 quarters · filed 2019-05-10 | |
| 2017-12-31 | $309.31K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $489.99K derived: sum of 2 quarters · filed 2019-02-26 | $801.58K derived: sum of 3 quarters · filed 2019-02-26 | $935.32K 10-K · filed 2019-02-26 | |
| 2017-09-30 | $180.68K 10-Q · filed 2018-11-09 | $492.27K derived: sum of 2 quarters · filed 2018-11-09 | $626.00K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $311.59K 10-Q · filed 2018-08-09 | $445.33K 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $133.74K 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | $280.36K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |